MENU 简体中文ENG
About Us
About Us

Founded in 2013 and headquartered in Shanghai, OBiO is a biotechnology company focusing on gene and cell therapy field: serving as a contract research organization for vectorology and functional genomics studies and providing contract development and manufacturing services of IND-enabling CMC, clinical and commercial manufacturing. In recent years, in line with the mission of enabling gene therapy for better lives, OBiO has established core technologies around vectorology development, large-scale process development and manufacturing, facilitating a robust and versatile GMP manufacturing system for various gene and cell therapy products.

We leverage the core technologies in vectorology research and large-scale manufacturing, persistently facilitating the discovery, research, clinical study and commercialization of gene and cell therapy products. Based in Shanghai, we offer a wide range of services to global customers, aiming to bring benefit to the whole world with on our technology platform.

History
2013
  • Founding of OBiO Technology (Shanghai) Corp., Ltd.
2014
  • Embarked on contract research services for gene therapy
  • Acquisition of Neuron Biotech, establish a leading position in contract research services of adeno-associated virus in China
2015
  • Series A financing completed
  • Industry-academia-research strategic collaboration with Chinese Academy of Medical Sciences (CAMS)
2016
  • Started the operation of research and development platform at SPIRO Site
  • Listed on National Equities Exchange and Quotations (NEEQ)
2017
  • Constructed and started operating the GLP pilot platform for viral vector at SPIRO Site
  • Global strategic collaboration with GE Healthcare on gene therapy
2018
  • First Pre-IND project of viral vector product
2019
  • Operation started at PINE Site with +5,000 sqm GMP footprint
  • Delisted from National Equities Exchange and Quotations (NEEQ)
  • Official registration of OBiO Intelli-M manufacturing site
2020
  • Completion of four rounds of financing
  • Scaled up to +7,000 sqm GMP footprint
  • Third-party GMP audit clearance
  • Supported the first oncolytic virus IND clearance in China, the United States and Australia
  • Embarked on the construction of OBiO Intelli-M at Lin-Gang Free-Trade Zone
2021
  • Successful IPO submission on STAR Board
  • Scaled up to +10,000 sqm GMP footprint
  • Supported multiple Phase II clinical studies
  • Initiation of AAVneO™ capsid screening platform with novel serotypes obtained
2022
  • Successful Listing on Shanghai Stock Exchange (SSE, code: 688238)
Future
In China, for Global Customers
Becoming a leading multi-service provider in biopharmaceutical industry
Our Facilities
As a trustful contract development and manufacturing organization, flexible capacities and regulatory compliant facilities are the prerequisites for providing high-quality services to gene and cell therapy developers. To offer services to worldwide customers, we have established an integrated research platform with over 5,000 sqm footprint, over 10,000 sqm GMP footprint at Shanghai International Medical Park, and a 77,000 sqm GMP manufacturing site at Lin-Gang Free-Trade Zone. We provide high-quality contract research and manufacturing services at three locations:
Leadership Team
OBiO is led by an experienced team of executives. Their professional background and cumulative expertise provide robust support for strong leadership that keeps OBiO at the frontier of the gene therapy industry.
CONTACT US
First Name*
Last Name*
Company*
Email*
Phone Number*
I'm interested in…
Questions or Comments
Security Code*
I AGREE*
By submitting this form I agree that OBiO may process my data in the manner described in OBiO’s Privacy Policy
We won’t share your information.
Upcoming Events
© 2022 OBiO Technology (Shanghai) Corp., Ltd. All Rights Reserved